Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O75344

UPID:
FKBP6_HUMAN

ALTERNATIVE NAMES:
36 kDa FK506-binding protein; FK506-binding protein 6; Immunophilin FKBP36

ALTERNATIVE UPACC:
O75344; B4DXT7; G3V0I2; Q7Z4T4; Q9UDS0

BACKGROUND:
The protein FKBP6, known for its alternative names such as 36 kDa FK506-binding protein and Immunophilin FKBP36, is integral to the process of spermatogenesis. It functions to suppress the mobilization of transposable elements, crucial for preserving germline integrity. FKBP6's interaction with HSP90 and involvement in the piRNA metabolic process underscore its role in the methylation and repression of transposons, essential for reproductive health.

THERAPEUTIC SIGNIFICANCE:
Given its association with Spermatogenic failure 77, characterized by significant male infertility, the study of FKBP6 offers a promising avenue for developing targeted therapies. Understanding the role of FKBP6 could open doors to potential therapeutic strategies, especially in the realm of reproductive health and fertility treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.